Despite the availability of around 30 anti-seizure drugs, drug-resistant epilepsy remains a significant clinical and societal burden. We report the first promising result of a new candidate BICS01.
Planegg / Martinsried (Germany) – January 7, 2022 – Bicoll, an expert in synthesizing new and relevant small molecules as starting points for accelerated drug development, worked together with its partners at the University College London, FutureNeuro, and Royal College of Surgeons to publish data for a promising anti-seizure drug candidate BICS01 in Frontiers in Neurology.
